AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 60988 — intervention group
Group type: COMPARATOR
Intervention: gamma globulin
Number of subjects: 507
Study 31988084 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening using a single-lead ECG device
Number of subjects: 17107
Study 31988084 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 17107
Study 31988084 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened patients
Number of subjects: 17107
Study 31988084 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with newly diagnosed AF in intervention practices
Number of subjects: 17107
Study 31660823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (DAAO inhibitor), 2 g per day for 6 weeks
Number of subjects: 0
Study 31660823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28745788 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nursing
Number of subjects: 106
Study 28745788 — intervention group
Group type: COMPARATOR
Intervention: Control group (COPD health education at discharge)
Number of subjects: 106
Study 25232809 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 μg per day from L-selenomethionine)
Number of subjects: 11267
Study 25232809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU per day of all rac-α-tocopheryl acetate)
Number of subjects: 11267
Study 25232809 — intervention group
Group type: COMPARATOR
Intervention: No selenium (control group)
Number of subjects: 11267
Study 25232809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group for vitamin E)
Number of subjects: 11267
Study 23817144 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch with Music (HTM)
Number of subjects: 0
Study 23817144 — intervention group
Group type: COMPARATOR
Intervention: Attention Control with Music (ACM)
Number of subjects: 0
Study 21709297 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE-restricted diet (<10 AGE Eq/day)
Number of subjects: 36
Study 21709297 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (>20 AGE equivalents [Eq]/day)
Number of subjects: 36
Study 19366132 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal incision technique
Number of subjects: 81
Study 19366132 — intervention group
Group type: COMPARATOR
Intervention: Traditional incision technique
Number of subjects: 81
Study 16369811 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MPA (0.625 mg/day + 2.5 mg/day)
Number of subjects: 58
Study 16369811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day)
Number of subjects: 58
Study 12771456 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogues plus ultrasound-guided aspiration of endometriomas
Number of subjects: 24
Study 12771456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracystic injection of recombinant interleukin-2 (rIL-2)
Number of subjects: 24
Study 12771456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rIL-2)
Number of subjects: 24
Study 11151733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordis Orbis Sigma valve
Number of subjects: 0
Study 11151733 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic PS Medical Delta valve
Number of subjects: 0
Study 11151733 — intervention group
Group type: COMPARATOR
Intervention: Standard valve designs
Number of subjects: 0
Study 9078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative thyroid hormone levels after cardiac surgery
Number of subjects: 132
Study 9078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative urinary iodine excretion
Number of subjects: 132
Study 9078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with postoperative T3 plasma concentrations less than 0.6 nmol/L
Number of subjects: 132
Study 9078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with dopamine
Number of subjects: 132
Study 9078538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative doses of inotropic and vasoactive catecholamines and furosemide
Number of subjects: 132
Study 8337017 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling regarding specific management techniques
Number of subjects: 38
Study 8337017 — intervention group
Group type: EXPERIMENTAL
Intervention: Car-ride simulation device
Number of subjects: 38
Study 8337017 — intervention group
Group type: COMPARATOR
Intervention: Control (reassurance and support)
Number of subjects: 38
Study 3725653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 85
Study 3725653 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (ampicillin and chloramphenicol)
Number of subjects: 85
Study 29798075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin as bridge therapy
Number of subjects: 58
Study 29798075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warfarin)
Number of subjects: 58
Study 25656505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention program (multidomain cognitive stimulation including art, music, recollection, and horticultural therapy, 1 hour each session, 5 times per week for 6 months)
Number of subjects: 53
Study 25656505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention program
Number of subjects: 53
Study 25656505 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacotherapy only)
Number of subjects: 53
Study 25010104 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy sessions (6 weekly 1-hour sessions)
Number of subjects: 30
Study 25010104 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic index (TI) measured using skin conductance resonance
Number of subjects: 30
Study 25010104 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective measure of therapeutic alliance (Working Alliance Inventory)
Number of subjects: 30
Study 25010104 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anxiety levels
Number of subjects: 30
Study 22159005 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (4 times a day with subsequent reduction)
Number of subjects: 110
Study 22159005 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 110
Study 20178588 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioners' views on diagnosing CFS/ME
Number of subjects: 22
Study 20178588 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of referral to secondary care
Number of subjects: 22
Study 17881145 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + short-course hormone therapy (STH)
Number of subjects: 2922
Study 17881145 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + long-term hormone therapy (LTH)
Number of subjects: 2922
Study 17881145 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 2922
Study 15954049 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus short‐duration passive stretch
Number of subjects: 150
Study 15954049 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus long‐duration passive stretch
Number of subjects: 150
Study 15954049 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 150
Study 14502032 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10713298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 60% VO(2peak) following caffeine consumption
Number of subjects: 8
Study 10713298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 60% VO(2peak) following placebo consumption
Number of subjects: 8
Study 10713298 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet rest following caffeine consumption
Number of subjects: 8
Study 10713298 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest following placebo consumption
Number of subjects: 8
Study 8666769 — intervention group
Group type: EXPERIMENTAL
Intervention: Swan-Gantz catheter inserted without skin contact
Number of subjects: 33
Study 8666769 — intervention group
Group type: COMPARATOR
Intervention: Single-lumen catheters with skin contact
Number of subjects: 33
Study 8666769 — intervention group
Group type: COMPARATOR
Intervention: Swan-Gantz sheets
Number of subjects: 33
Study 2000777 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 0
Study 6140229 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol (Inderal)
Number of subjects: 15
Study 31438901 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy A - Directly to families
Number of subjects: 0
Study 31438901 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy B - To teaching staff only
Number of subjects: 0
Study 31438901 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy C - To health service staff only
Number of subjects: 0
Study 31438901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29368599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 20 L/min, low leakage
Number of subjects: 36
Study 29368599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 40 L/min, low leakage
Number of subjects: 36
Study 29368599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 40 L/min, high leakage (one prong outside and open)
Number of subjects: 36
Study 29368599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 40 L/min, high leakage (one prong outside and closed)
Number of subjects: 36
Study 29368599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF) at 40 L/min, low leakage (condition B)
Number of subjects: 36
Study 27450228 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (exact dosage and duration not specified)
Number of subjects: 0
Study 27450228 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (gastric acid-reducing agent, exact dosage and duration not specified)
Number of subjects: 0
Study 25419180 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic pretreatment
Number of subjects: 925
Study 25419180 — intervention group
Group type: EXPERIMENTAL
Intervention: Age above median
Number of subjects: 925
Study 25419180 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid pretreatment
Number of subjects: 925
Study 22133040 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based patient information
Number of subjects: 1120
Study 22133040 — intervention group
Group type: COMPARATOR
Intervention: Standard patient information
Number of subjects: 1120
Study 19860569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 10.6 microm and 650 nm laser acupuncture‐moxibustion on acupoint Dubi (ST35)
Number of subjects: 40
Study 19860569 — intervention group
Group type: COMPARATOR
Intervention: Nonacupoint sham control
Number of subjects: 40
Study 17593127 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 5Hz repetitive TMS
Number of subjects: 17
Study 17593127 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17
Study 17593127 — intervention group
Group type: COMPARATOR
Intervention: Active 1Hz repetitive TMS
Number of subjects: 17
Study 15674313 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g CLA isomer blend (50:50% cis-9,trans-11:trans-10,cis-12 isomers)
Number of subjects: 60
Study 15674313 — intervention group
Group type: COMPARATOR
Intervention: Palm/bean oil blend (placebo)
Number of subjects: 60
Study 12666951 — intervention group
Group type: COMPARATOR
Intervention: EDTA gel conditioning for 2 minutes (G3)
Number of subjects: 48
Study 12666951 — intervention group
Group type: COMPARATOR
Intervention: EDTA gel conditioning for 2 minutes after scaling and root planing (G4)
Number of subjects: 48
Study 12666951 — intervention group
Group type: COMPARATOR
Intervention: EDTA gel conditioning for 4 minutes after scaling and root planing (G5)
Number of subjects: 48
Study 12666951 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing only (G2)
Number of subjects: 48
Study 12666951 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA gel conditioning for 4 minutes (G5)
Number of subjects: 48
Study 11110015 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 25
Study 11110015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11110015 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 25
Study 8899469 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 25
Study 8899469 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 25
Study 7105952 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg tds)
Number of subjects: 26
Study 7105952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31453927 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based couple intervention
Number of subjects: 487
Study 31453927 — intervention group
Group type: COMPARATOR
Intervention: Invitation letter for clinic-based couple HIV testing
Number of subjects: 487
Study 27894036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and brief psychodynamic psychotherapy (IBPP)
Number of subjects: 149
Study 27894036 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 149
Study 25602290 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus manualized CBT informed Victim Improvement Package (VIP)
Number of subjects: 26
Study 25602290 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 26
Study 24737459 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia at discharge
Number of subjects: 3731
Study 24737459 — intervention group
Group type: COMPARATOR
Intervention: Baseline anemia
Number of subjects: 3731
Study 24737459 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge anemia
Number of subjects: 3731
Study 24737459 — intervention group
Group type: COMPARATOR
Intervention: No anemia at baseline
Number of subjects: 3731
Study 22250828 — intervention group
Group type: EXPERIMENTAL
Intervention: Loozit® weight management programme with additional therapeutic contact via telephone coaching and electronic communications
Number of subjects: 12
Study 22250828 — intervention group
Group type: COMPARATOR
Intervention: Loozit® weight management programme
Number of subjects: 12
Study 19254366 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of IGOB131
Number of subjects: 102
Study 19254366 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 102
Study 17451414 — intervention group
Group type: EXPERIMENTAL
Intervention: Behçet's disease patients (BD)
Number of subjects: 86
Study 17451414 — intervention group
Group type: COMPARATOR
Intervention: Recurrent aphthous stomatitis patients (RAS)
Number of subjects: 86
Study 17451414 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 86
Study 10749962 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal angioplasty
Number of subjects: 106
Study 10749962 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 106
Study 8874746 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical melatonin 0.5%
Number of subjects: 20
Study 8874746 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical melatonin 0.05%
Number of subjects: 20
Study 8874746 — intervention group
Group type: COMPARATOR
Intervention: Carrier alone
Number of subjects: 20
Study 1573135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention
Number of subjects: 894
Study 1573135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 894
Study 4014216 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted telephone interviewing
Number of subjects: 400
Study 4014216 — intervention group
Group type: COMPARATOR
Intervention: Hard copy telephone interviewing
Number of subjects: 400
Study 30761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin + Phytolysin (3g fosfomycin single dose, Phytolysin three times daily for a month)
Number of subjects: 63
Study 30761783 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin (3g single dose)
Number of subjects: 63
Study 30761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin + Phytolysin
Number of subjects: 63
Study 30761783 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin
Number of subjects: 63
Study 26549151 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward
Number of subjects: 180
Study 26549151 — intervention group
Group type: EXPERIMENTAL
Intervention: Punishment
Number of subjects: 180
Study 26549151 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study 24762149 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic cancellous bone sponge
Number of subjects: 25
Study 22955035 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI (500/25 mcg)
Number of subjects: 51
Study 22955035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 20980494 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet (LoGIX; 40 ± 0.3 units)
Number of subjects: 22
Study 20980494 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index diet (HiGIX; 80 ± 0.6 units)
Number of subjects: 22
Study 20980494 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (1 h/d for 5 d/wk at ≈ 85% of maximum heart rate)
Number of subjects: 22
Study 18622640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (180-540 mg daily for 6 weeks)
Number of subjects: 10
Study 18622640 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (acute effects assessed)
Number of subjects: 10
Study 18622640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 weeks)
Number of subjects: 10
Study 15842865 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation group (30 patients)
Number of subjects: 58
Study 15842865 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 patients)
Number of subjects: 58
Study 12699092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12699092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.15 mg
Number of subjects: 100
Study 12699092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 100
Study 12699092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg
Number of subjects: 100
Study 10598611 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (300 mg)
Number of subjects: 44
Study 10598611 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline control
Number of subjects: 44
Study 10598611 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline-intravenous lidocaine infusion
Number of subjects: 44
Study 8524760 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy and a course of microwave therapy
Number of subjects: 136
Study 8524760 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 136
Study 1957647 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblast injection (approximately 8 x 10(6) myoblasts)
Number of subjects: 3
Study 1957647 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (carrier solution)
Number of subjects: 3
Study 1957647 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblast injection with Cyclosporine (CsA) treatment (started two days before injection and continued for three months)
Number of subjects: 3
Study 31419219 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational intervention (n = 153)
Number of subjects: 305
Study 31419219 — intervention group
Group type: COMPARATOR
Intervention: No additional intervention (control group; n = 152)
Number of subjects: 305
Study 31419219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 305
Study 31419219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with workplace visit (n = 40)
Number of subjects: 305
Study 28153946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 35
Study 28153946 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 35
Study 26819953 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 17
Study 26819953 — intervention group
Group type: COMPARATOR
Intervention: Placebo Taping (PT)
Number of subjects: 17
Study 23381945 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in patients with moderate Wwox expression
Number of subjects: 912
Study 23381945 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in patients with strong Wwox expression
Number of subjects: 912
Study 23381945 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients with absent Wwox expression
Number of subjects: 912
Study 21277076 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 90
Study 21277076 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-Secur
Number of subjects: 90
Study 21277076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Arc
Number of subjects: 90
Study 21181319 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (80 mg/30 minutes, then 8 mg/hour for 71.5 hours)
Number of subjects: 764
Study 21181319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 764
Study 21181319 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 764
Study 16504281 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 30
Study 16504281 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% carbamide peroxide
Number of subjects: 30
Study 16504281 — intervention group
Group type: COMPARATOR
Intervention: 0% carbamide peroxide (control)
Number of subjects: 30
Study 15585551 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial substitution of 50 microg T4 by 10 microg T3
Number of subjects: 697
Study 15585551 — intervention group
Group type: COMPARATOR
Intervention: Original dose of T4 (control group)
Number of subjects: 697
Study 12038448 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step high-dose chemotherapy (HDT) with autologous peripheral blood progenitor cell (PBPC) transplant
Number of subjects: 20